These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 17055014

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
    Humphreys WG, Unger SE.
    Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
    [Abstract] [Full Text] [Related]

  • 5. Metabolites in safety testing.
    Robison TW, Jacobs A.
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [Abstract] [Full Text] [Related]

  • 6. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
    Powley MW, Frederick CB, Sistare FD, DeGeorge JJ.
    Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
    [Abstract] [Full Text] [Related]

  • 7. Safety testing of metabolites: Expectations and outcomes.
    Pang KS.
    Chem Biol Interact; 2009 Apr 15; 179(1):45-59. PubMed ID: 18926805
    [Abstract] [Full Text] [Related]

  • 8. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
    Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, Nedderman A, Obach RS, Wright P.
    Chem Res Toxicol; 2009 Oct 15; 22(10):1653-62. PubMed ID: 19715349
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials.
    Food Chem Toxicol; 2008 Mar 15; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [Abstract] [Full Text] [Related]

  • 11. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
    Zhu M, Zhang D, Zhang H, Shyu WC.
    Biopharm Drug Dispos; 2009 May 15; 30(4):163-84. PubMed ID: 19544287
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Interpretation and considerations on the safety evaluation of human drug metabolites.
    Atrakchi AH.
    Chem Res Toxicol; 2009 Jul 15; 22(7):1217-20. PubMed ID: 19563206
    [Abstract] [Full Text] [Related]

  • 14. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
    Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, Evans DC.
    Chem Res Toxicol; 2009 Feb 15; 22(2):280-93. PubMed ID: 19183054
    [Abstract] [Full Text] [Related]

  • 15. A regulatory perspective on issues and approaches in characterizing human metabolites.
    Davis-Bruno KL, Atrakchi A.
    Chem Res Toxicol; 2006 Dec 15; 19(12):1561-3. PubMed ID: 17173368
    [Abstract] [Full Text] [Related]

  • 16. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K, Babalola K, Wang J, Espina R, Yu L, Adedoyin A, Talaat R, Mutlib A, Scatina J.
    Chem Res Toxicol; 2009 Feb 15; 22(2):311-22. PubMed ID: 19067650
    [Abstract] [Full Text] [Related]

  • 17. Human radiolabeled mass balance studies: objectives, utilities and limitations.
    Penner N, Klunk LJ, Prakash C.
    Biopharm Drug Dispos; 2009 May 15; 30(4):185-203. PubMed ID: 19544285
    [Abstract] [Full Text] [Related]

  • 18. Strategy for genotoxicity testing--metabolic considerations.
    Ku WW, Bigger A, Brambilla G, Glatt H, Gocke E, Guzzie PJ, Hakura A, Honma M, Martus HJ, Obach RS, Roberts S, Strategy Expert Group, IWGT.
    Mutat Res; 2007 Feb 03; 627(1):59-77. PubMed ID: 17141553
    [Abstract] [Full Text] [Related]

  • 19. From known knowns to known unknowns: predicting in vivo drug metabolites.
    Pelkonen O, Tolonen A, Korjamo T, Turpeinen M, Raunio H.
    Bioanalysis; 2009 May 03; 1(2):393-414. PubMed ID: 21083174
    [Abstract] [Full Text] [Related]

  • 20. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
    Baillie TA.
    Chem Res Toxicol; 2009 Feb 03; 22(2):263-6. PubMed ID: 19216579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.